Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans

Arvat, Emanuela; Vito, Lidia Di; Broglio, Fabio; Papotti, Mauro; Muccioli, Giampiero; Diéguez, Carlos; Casanueva, Felipe F.; Deghenghi, Romano; Camanni, F.; Ghigo, Ezio

doi:10.1007/bf03343763

Cited by 334 publications

(222 citation statements)

References 9 publications

Supporting

Mentioning

201

Contrasting

Unclassified

Order By: Relevance

“…6.79x10 6 copy number/µg total RNA in normal tissue vs 1.41x10 7 in malignant tissue, p=not significant.…”

Section: Vegf-189mentioning

confidence: 91%

“…Ghrelin acts directly on the anterior pituitary gland to stimulate GH release, and in vivo studies in humans involving intravenous injections of ghrelin demonstrate that the GH response to ghrelin is greater than that to GHRH 7 . However, despite its potent effect on GH release, there is some doubt over the primary role for ghrelin in the regulation of GH secretion, following a report indicating that no specific phenotype was observed in a ghrelin knockout mouse 8 .…”

Section: Ghrelinmentioning

confidence: 99%

See 1 more Smart Citation

The GH–IGF-I axis and breast cancer

Laban

Bustin

Jenkins

2003

Trends in Endocrinology & Metabolism

109

View full text Add to dashboard Cite

“…6.79x10 6 copy number/µg total RNA in normal tissue vs 1.41x10 7 in malignant tissue, p=not significant.…”

Section: Vegf-189mentioning

confidence: 91%

Section: Ghrelinmentioning

confidence: 99%

The GH–IGF-I axis and breast cancer

Laban

Bustin

Jenkins

2003

Trends in Endocrinology & Metabolism

109

View full text Add to dashboard Cite

“…Ghrelin, the endogenous ligand specific for the growth hormone (GH) secretagogue receptor, was discovered in 1999 by Kojima et al 1 Besides being a strong stimulator of GH secretion, 2,3 several studies have reported ghrelin to be a potent peptide involved in appetite and food regulation, as it increases food intake and promotes adiposity in both humans and animals. [4][5][6] Reduced levels have been reported in obese subjects, 7,8 whereas increased concentrations have been found in patients with anorexia nervosa.…”

Section: Introductionmentioning

confidence: 99%

Meal suppression of circulating ghrelin is normalized in obese individuals following gastric bypass surgery

et al. 2006

View full text Add to dashboard Cite

Objective: It has been proposed that the success of maintained weight loss in morbidly obese subjects following Roux-en-Y gastric bypass (RYGBP) surgery depends on inappropriately low circulating concentrations of the appetite-stimulating peptide ghrelin, being unresponsive to food intake. In this study, this hypothesis was examined. Design: Cross-sectional study with repeated blood samples in 40 subjects after 14 h of prolonged overnight fasting followed by a standardized mixed meal (770 kcal). Subjects: Twenty men and 20 women were included: 10 middle-aged morbidly obese (body mass index (BMI) 43.973.3 kg/ m 2 ), 10 middle-aged subjects who had undergone RYGBP at the Uppsala University Hospital (BMI 34.775.8 kg/m 2 ), 10 middleaged non-obese (BMI 23.572.2 kg/m 2 ) and 10 young non-obese (BMI 22.771.8 kg/m 2 ). Measurements: Ghrelin, glucose and insulin levels were analysed pre-and postprandially. Results: In the morbidly obese, ghrelin concentrations were lower in the morning than in the RYGBP group and did not change following the meal. In the RYGBP group, fasting ghrelin levels fell after meal intake and showed similar suppression as both agematched and young non-obese controls. The RYGBP surgery resulted in an increased meal-induced insulin secretion, which was related to the degree of postprandial ghrelin suppression. Conclusion: The present study demonstrates low circulating concentrations of ghrelin and blunted responses to fast and feeding in morbidly obese subjects. Marked weight reduction after RYGBP at our hospital is followed by a normalization of ghrelin secretion, illustrated by increased fasting levels compared to the preoperative obese state and regain of meal-induced ghrelin suppression.

show abstract

“…IGFBP-1 concentrations were associated with ghrelin concentrations only in subjects with IR. Since ghrelin has a powerful GH-releasing effect in experimental settings [1,8,17,18], it has been proposed to serve as a regulator of somatotroph function together with GHRH and somatostatin [39,40]. However, the physiological role of ghrelin in the regulation of GH/IGF-I axis has not yet been established.…”

Section: Discussionmentioning

confidence: 99%

“…Despite the fact that ghrelin has a powerful, rapid, and dose-dependent effect on GH release in experimental studies [1,17,18], the functional role of ghrelin in the long-term regulation of GH concentrations in physiological conditions has not yet been clarified. The recent studies are either for [19][20][21][22] or against [23][24][25][26] the role of ghrelin in the regulation of GH concentrations.…”

mentioning

confidence: 99%

The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes

et al. 2005

View full text Add to dashboard Cite

Aims/hypothesis: Ghrelin is a natural growth hormone-releasing peptide thought to be involved in the regulation of energy metabolism. The recent studies concerning the association between ghrelin and insulin-like growth factor-I (IGF-I) concentrations have shown either negative correlation or no correlation at all. The aims of this study were to clarify the association between ghrelin and IGF-I concentrations in a large cohort and to characterize whether obesity, insulin resistance and type 2 diabetes affect this association. Methods: We analysed fasting plasma ghrelin and IGF-I concentrations of 1,004 middleaged subjects of the population-based OPERA study. Insulin resistance was estimated using QUICKI. Results: IGF-I concentrations were negatively associated with ghrelin concentrations in the analysis of all subjects before (β= −0.32, p<0.001) and after adjustments for BMI, insulin levels, sex and age (β=−0.40, p<0.001). The association was particularly strong in males and in the higher BMI tertiles. The degree of association varied in relation to the glycaemic status: no insulin resistance: r 2 =6.5% (p<0.001), insulin resistance without type 2 diabetes: r 2 =21.0% (p< 0.001), type 2 diabetes: r 2 =25.4 (p<0.001). IGF-I levels explained larger proportion (r 2 =9.8%) of the variation in ghrelin concentrations compared to fasting insulin concentration (r 2 =3.0%) and BMI (r 2 =1.5%). Conclusions/ interpretation: There is a negative and independent association between ghrelin and IGF-I concentrations in middleaged subjects. The interaction between IGF-I and ghrelin is modified by obesity, IR and type 2 diabetes. Further studies are warranted to elucidate the role of ghrelin in the development of these states.

show abstract

Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans

Cited by 334 publications

References 9 publications

The GH–IGF-I axis and breast cancer

The GH–IGF-I axis and breast cancer

Meal suppression of circulating ghrelin is normalized in obese individuals following gastric bypass surgery

The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes

Contact Info

Product

Resources

About